| |
 |
 |
 |
 |
 |
 |
 |
September 25, 2002
Greetings:
Announcement of Listing
Representative Director and Vice President |
 |
|
|
Ei Yamada
On September 25, 2002, AnGes MG achieved a listing on the Mothers
index of Tokyo Stock Exchange. Let me take this opportunity
to express sincere feelings of appreciation for the continued
support we receive from all our investors, as well as everyone
else involved.
Our Company was founded in December 1999 by (people like) Associate
Professor Morishita of Osaka University, for the purpose of
commercializing the HGF (Hepatocyte Growth Factor) genetic therapy.
The genetic medication represents a new kind of pharmaceuticals,
principally different from all other drugs we have seen before.
While considerable therapeutic effects are expected, pharmaceutical
companies have been unable to develop genetic agents because
such development is accompanied by very high risk to human lives.
We develop such medication - it is our mission to provide patients
with innovative drugs to cure diseases for which no fundamental
therapy has been available to date.
The HGF genes we are working with are responsible for blood
vessel regeneration and improvement of blood circulation. For
example, severe ischemic disease causes the blood vessels of
legs to clog, which can then lead to a patient's lower limb(s)
amputated. HGF genes may ease/alter the condition and (help)
avoid amputation of leg(s). We also endeavor to put the remarkable
technologies of NF- B
decoy oligo nucleotides (cures inflammatory diseases by controlling
genetic expressions) and HVJ envelope vectors (helps analyze
genetic functions for drugs reach to affected parts) to practical
application.
Generally, it takes a tremendous amount of time and funds to
develop a pharmaceutical product, and such efforts may not necessarily
come to fruition. To survive such a high-risk environment, cooperation
with pharmaceutical companies is the most vital element in the
business strategy, our Company being a venture enterprise. We
envision a business model in which our development costs are
shared by the pharmaceutical companies, whereas our income comes
from royalties (licensing fees) once a product is marketed,
so that a stable flow of earnings can be secured. The listing
on Mothers enables us to stabilize our financial base, at the
same time allowing us to enforce research and development -
our Company's lifeline.
We strive to minimize financial risks at the development stage
to be able to increase our income base at the sales stage, scheduled
in 2005. We also do our best to make information available to
investors and general public, to generate awareness about our
products and technologies. The listing in Mothers is just once
step further on the way to meeting the expectations of patients,
stockholders and investors. Once again, let me take this opportunity
to thank you all for your continued support. |
|
|
